Fig. 3From: Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36 monthsChanges in abundance levels, expressed as the natural logarithm of the score fold change (ln[T36/T0]) for smooth muscle proteins (SMPs) in omalizumab responders (OR) and non-omalizumab responders (NOR) at baseline (T0) and after 36 months (T36) of treatment. A negative value indicates a decrease in SMPs at T36; a positive value indicates an increase in SMPs at T36. OR and NOR are classified according to whether they experienced a reduction in RBM thickness (OR) or no reduction in RBM thickness (NOR) after 12 months of anti-IgE treatmentBack to article page